Quarterly ResultMay 7, 2026, 04:35 PM
Revelation Biosciences Q1 Net Loss $3.0M; Cash $14.1M
AI Summary
Revelation Biosciences reported a net loss of $3.0 million for the first quarter ended March 31, 2026, compared to a $2.1 million net loss in Q1 2025. The company's cash and cash equivalents increased to $14.1 million from $10.7 million at year-end 2025, primarily due to $6.7 million in net proceeds from a January 2026 warrant inducement. Revelation Biosciences also announced an agreement with the FDA for a single adaptive Phase 2/3 study for Gemini in acute kidney injury and expects current cash to fund operations through Q1 2027.
Key Highlights
- Net loss for Q1 2026 was $3.0 million, up from $2.1 million in Q1 2025.
- Basic and diluted net loss per share was $2.71 for Q1 2026.
- Cash and cash equivalents totaled $14.1 million as of March 31, 2026.
- Received $6.7 million in net proceeds from a warrant inducement in January 2026.
- Net cash used for operating activities was $3.2 million in Q1 2026.
- Cash runway extends through the first quarter of 2027.
- FDA agreement reached for a single adaptive Phase 2/3 study for Gemini in acute kidney injury.